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The effects of repetitive transcranial
magnetic stimulation in obese females
with binge eating disorder: a protocol
for a double-blinded, randomized,
sham-controlled trial
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Clarissa Mollinero Picasso1, Arthur Berberian2, Iain Campbell3, Ulrike Schmidt3 and Angélica Medeiros Claudino1*
Abstract
Background: Binge eating disorder is a new category in DSM-5 and highly associated with higher body mass
index. The neural mechanisms that underlie binge eating are of great interest in order to improve treatment
interventions. Brain mechanisms underlying drug and food craving are suggested to be similar: for example, both
are reported to be associated with increased neural activity in the orbitofrontal and anterior cingulate cortex, and a
diminished regulatory influence from lateral prefrontal circuits. Several studies have begun to assess the potential
benefits of brain stimulation in reducing craving and addictive behaviors. Data from a study of a one-off session of
transcranial magnetic stimulation in healthy women identified as strong cravers and of individuals with bulimic-type
eating disorders, reported a reduction in food craving and binge eating episodes. This provides support for a more
extensive investigation of the potential therapeutic benefits of transcranial magnetic stimulation. Lastly, brain
imaging studies and a dimensional approach, will improve understanding of the neural correlates of the disorders
and of the mode of action of transcranial magnetic stimulation.
Methods/Design: Sixty eligible obese females, with binge eating disorder, will be randomly allocated to receive 20
sessions of transcranial magnetic stimulation intervention (n = 30) or the sham transcranial magnetic stimulation
intervention (n = 30) scattered 3 days/week. Thirty eligible controls will complete the baseline assessment. The
primary outcome (number of binge eating episodes) will be assed at each treatment sessions, and 8 weeks after
intervention completion (follow-up). It is hypothesized that mean weekly binge-eating episodes will be reduced in
the intervention group, compared to the sham group, and that the effect will be maintained at follow-up.
Discussion: Despite the severity associated with Binge Eating Disorder, there are limited treatment options. This
study is an important step in the development of more effective treatments. Importantly, the study is the first to
investigating binge eating disorder using a dimensional approach, by looking at the different aspects of the
disorder, such as behavioral factors, biological factors, brain circuits and chemistry.
Trial registration: Clinical Trials NCT02180984. Registered in July 2014.
Keywords: Binge eating disorder, Transcranial magnetic stimulation, Neuroimaging, Hormones, Eating disorders,
Obesity, Control inhibition, Eating disorders
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Binge Eating Disorder (BED) is characterized by recurrent
episodes of excessive food consumption with experienced
loss of control over eating and marked distress, which are
not regularly followed by inappropriate compensatory be-
haviors [1]. Originally, BED was introduced in the 4th edi-
tion of the Diagnostic and Statistical Manual of Mental
Disorder (DSM-IV) as a subcategory of Eating Disorder
not Otherwise Specified (EDNOS) [2], but is now a separ-
ate diagnostic entity. The DSM-5 diagnostic criterion for
BED includes significant changes. The minimum average
frequency of binge eating (BE) has been reduced from at
least twice/week for six months to at least once/week for
three months.
BED is a clinically significant disorder affecting a broader
range of individuals than anorexia nervosa (AN) and bu-
limia nervosa (BN) [3]. The lifetime prevalence of BED is
higher in overweight and obese population [4], with num-
bers as high as 51 % of individuals seeking help in weight
loss programs in Latin America [5]. In addition, BED is a
long-term disorder, with a mean lifetime duration of
14.4 years [6] and, lastly, it is associated with significant
impairment in quality of life, i.e. (both physical and mental
health) [4, 7].
Despite the emotional and physiological consequences
of BED, effective treatment associated with a long-term
impact on weight is limited. Cognitive Behavioral Therapy
(CBT) is currently the treatment of choice: it is reported
to result in a 60 % long-term (one year) reduction in BE
[8, 9]. However, with respect to weight loss, the impact of
psychological interventions for BED is limited [10]. Simi-
larly, despite reducing the frequency of BE, drug treat-
ments are associated with little effect on weight, (with few
exceptions such as sibutramine and topiramate [10–12]).
Unfortunately, these medications are associated with
safety restrictions: sibutramine has been withdrawn from
the market in many countries, and topiramate has been
associated with low tolerability [13]. Importantly, the pau-
city of information on the pathophysiological mechanisms
underlying BED, is limiting further advances in treatment.
It is clear that, there is a need for a broader investiga-
tion of the mechanisms that are involved in the genesis
and maintenance of BED, e.g. of the neurobiological pro-
cesses underpinning bulimic behaviors and weight regu-
lation. This type of exploration is in accordance with the
US National Institute of Mental Health (NIMH) and the
Research Domain Criteria (RDoC), which is a new re-
search approach scientists are being encouraged to adopt
it. In essence, the RDoC is a dimensional research ap-
proach that investigates mental disorders by looking at
different aspects, such as behavioral factors, biological
factors, brain circuits and chemistry [14]. The current
project was based on the RDoC approach and guidelines;
hence, different units of analysis and aspects of BED will
be investigated.
Psychoneuroendocrinological and immunological aspects of
BED and obesity: food craving, stress, hormones and their
association with control inhibition and compulsive eating
There is increasing interest in the conceptualization of
disordered eating as a food addiction. This is substan-
tially based on the fact that that addictions and bulimic
type ED share phenomenological characteristics such as
escalating frequency of the behavior, increased salience
of food/drug stimuli, ambivalence towards treatment
and frequent relapse [15, 16]. In terms of brain mecha-
nisms, individuals who are drug addicts and obese (with
and without BED), are reported to have decreased DA
D2 receptor density in the striatal regions [17–19]: this
may reduce the sensitivity to natural rewards and en-
hance impulsivity [20]. It has been hypothesized that im-
pulsivity results from failures of response inhibition or
‘top down’ cognitive control involved in the activity of
the prefrontal cortex (PFC), specifically the dorsolateral
prefrontal cortex (DLPFC). Individuals with effective
dietary self-control have increased activity in the left
DLPFC when making decisions about food ingestions
[21], suggesting that the DLPFC may be important for
regulatory control over food consumption.
Abnormalities in the food reward system and BE may be
associated with emotional and physiological stress. Cortisol,
the primary effector of the hypothalamic-pituitary-
adrenal (HPA) axis, may mediate stress-induced eating
and play a role in disordered eating [22]. Stress is not only
associated with disruption of the HPA axis, but may also
sensitize pro-inflammatory responses known to take part
in the pathogenesis of several ill-health conditions, includ-
ing psychiatric disorders and obesity. For instance, the adi-
pose tissue is part of the endocrine and innate immune
systems [23]. During the fat storage process, adipose tissue
produces inflammatory cytokines, such as C-reactive pro-
tein, TNF-alpha and IL-6. Importantly, adiponectin syn-
thesis is reduced in obese individuals [24], and the
mechanism that trigger the peripheral inflammation has a
cascade effect in the hypothalamus [25], leading to the
dysregulation in the physiological responses that main-
tains the sensitivity to insulin, leptin, ghrelin and peptide
tyrosine tyrosine (PYY). Furthermore, stress and inflam-
mation have been implicated in the disruption of synaptic
signaling and integrity, a process mediated in part through
the inhibition of neurotrophins’ function, in which BDNF
is the most extensively characterized [26]. Beyond its im-
portance in neural development and synaptic plasticity,
there is evidence [27] indicating that BDNF is also essen-
tial for weight control and is involved in both homeostatic
and non-homeostatic eating. In animal models [28], BDNF
has anorexigenic effects in the hypothalamus.
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Ovarian hormones are also involved in regulating food
intake. Exacerbation of BE seems to occur when estrogen
levels are low (premenstrual phase), and when progester-
one levels are high (mid-luteal phase) [29]. Estrogen is
mostly produced in the ovaries, but also in the liver, ad-
renal glands and fat tissue. Together with progesterone,
ghrelin, leptin, PYY and BDNF, estrogen has a role in ap-
petite regulation [30]. It is known that hormonal dysregu-
lation, including estrogen, has an impact on mood, body
weight and shape satisfaction, and on anxiety symptoms
[31]. Further, estrogen has both anti-inflammatory and
pro-inflammatory roles in the nervous system [32].
Cognition & neuropsychological evaluation of BED
Neuropsychological research involving individuals with
BED has demonstrated that in this group, cognitive per-
formances are poorer on some executive functional tasks,
such as, set shifting, inhibitory control [33], planning, de-
cision making [34, 35], problem solving, attention, and
working memory [36] than in healthy controls. However,
the exactly cognitive profile and mechanism abnormalities
of individuals with BED have not been established yet.
Notably, the literature suggests that a similar cognitive im-
pairment profile is present in obese individuals with or
without BED, indicating that cognitive deficits may be re-
lated to obesity itself rather than to the ED [33, 34, 37],
pointing out the need for further research.
Moreover, the use of neuropsychological instruments
along with neuroimaging is important to identify mild
cognitive impairments and create the opportunity to
distinguish brain patterns associated with a specific dis-
order. A recent study [38] that used fMRI to investigate
the neural correlates of inhibitory control in obese partici-
pants with BED (n = 35) found hypoactivity in brain re-
gions involved in self-regulation and impulse control in
obese BED participants during a cognitive control task
(Stroop test) compared with obese non-BED and lean
controls. The obese group with BED showed diminished
activity in the ventromedial prefrontal cortex (vmPFC), in-
ferior frontal gyrus (IFG) and insula. The authors con-
cluded that the abnormalities in the activation of brain
areas related to inhibition control in obese people with
BED support the hypothesis that obese binge eaters differ
from other obese individuals in regards to neurobiological
aspects, including inhibitory control abilities. The study
was the first to investigate the neural correlates of control
inhibition in obese individuals with BED in comparison to
lean controls.
The CPT-IP is a tool used to evaluate behavior inhib-
ition and cognitive impulsivity [39]. A recent and small
fMRI study with healthy subjects, using CPT to investi-
gate brain regions involved during the CPT perform-
ance: it identified the left cerebellum and the frontal,
temporal and occipital cortical brain areas. The ACC
was identified with the greatest activation cluster during
the same task [40]. Studies report that rTMS may lead
to a better cognitive performance [41, 42], however fur-
ther studies are necessary to understand its mechanisms
of actions.
Repetitive Transcranial Magnetic Stimulation (rTMS) for
the treatment of BED
It has not been established whether the clinical benefit of
any of the rTMS protocols in psychiatric disorders are a
direct or indirect consequence of the modulation of neur-
onal excitability. It has been proposed that the associated
release of neuromodulators and growth factors, e.g., brain
derived neurotrophic factor (BDNF) [43], play a role in
the mechanisms of action of rTMS [44].
There are pilot research studies on the effects of TMS
on food cravings and bulimic behaviors in humans. A
groundbreaking research study [45], demonstrated that
rTMS applied to the left PFC might inhibit food craving
compared to sham rTMS in healthy women considered
“strong cravers.” An earlier small (n = 14) and unpow-
ered, randomized, sham controlled trial found no benefit
for the use of rTMS to control bingeing or purging
behaviors in bulimic subjects [46]. In contrast, a subse-
quent proof-of-concept trial [47] reported positive find-
ings of a one-off session of real rTMS compared to
sham treatment for the reduction of food craving and
BE in the 24 h follow-up in individuals with bulimic-
type disorders. Furthermore, two recent reports have
demonstrated rTMS to be an effective treatment for re-
fractory bulimic-type ED. The first case report described
a female with a diagnosis of both refractory BN and co-
morbid depression [48], and demonstrated that 20 ses-
sions of rTMS (five sessions per week over four weeks)
ameliorated depression symptoms, BE behaviors and
purging, during the treatment. The second and most re-
cent case report [49], described a young female diag-
nosed with refractory BED and comorbid depression.
She was treated with 20 sessions of rTMS to the left
DLPFC for 30 min/session at 10Hz for one month [2400
stimuli per day]),: this resulted in partial, but significant
remission of depression symptoms and BE. Durability of
clinical benefit of rTMS treatment has not been estab-
lished, but studies that examined the short-term durability
of rTMS effects on depressive symptomology demon-
strated positive results [50, 51]. Repetitive TMS also holds
promise as a tool for managing brain network plasticity
properties and modulating cognitive abilities [52], and
there is evidence that the intervention might be associated
with up regulation of BDNF and possible neuroprotective
effects [53].
Studies have also addressed the impact of rTMS on HPA
axis function in humans [54, 55]. To date, the most con-
sistent results are found for individuals with depression
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disorder. In this population, rTMS seems to reduce HPA
axis activity. The effects of rTMS on the stress response in
patients with bulimic-type ED have also been investigated
in a double-blinded randomized sham-controlled trial
study [47]: twenty-two female participants received a one-
off session of high-frequency rTMS delivered to the left
DLPFC, and salivary cortisol levels were assessed at four
time points throughout the 90-min trial. Results showed
that salivary cortisol concentrations of individuals receiving
real rTMS were significantly lower compared to the indi-
viduals receiving sham rTMS.
Based on previous findings, rTMS is an important re-
search tool to investigate the neurobiology of craving and
BE. Thus, the current randomized controlled trial was de-
veloped to investigate the effects of rTMS on food craving
and BE behavior, but secondary aims include the study of
its effects on ED-related psychopathology (including
depression, anxiety and stress symptoms), anthropometric
measures, cognition, brain structure and function, hor-
mones and inflammatory biomarkers. In addition, toler-
ability and safety of rTMS will be examined.
The study will provide the opportunity to enhance the
knowledge on etiological similarities between addictions
and bulimic disorders. It will also enable the investiga-
tion of the interplay of neurobiological mechanisms that
are potentially involved in the pathogenesis of BED, and
which might be vulnerable to the effects of rTMS.
Hypothesis
Primary hypothesis:
The rTMS intervention will lead to the reduction of
BE frequency and food craving.
The secondary hypotheses
a) rTMS will promote a reduction in ED
psychopathology (BES, TEF-Q, LOCES, BSQ,) and
associated psychopathology (DASS-21, UPPS), a
reduction of anthropometric measures (BMI, hip-waist
circumference ratio) and an improvement in
neurocognitive performance (Stroop test, executive
functioning battery, particularly the CPT-IP).
b) Following rTMS, plasma leptin and estrogen will be
decreased along with cortisol levels and
proinflammatory biomarkers (PCR, TNF-alpha, IL-6,
IL-10) and that there will be an increase in plasma
levels of ghrelin (in participants with >20 % of weight
reduction), in levels of PYY and BNDF, as well as other
anti-inflammatory biomarkers (adiponectin and IL-2).
c) Participants will show that better inhibitory
responses and greater activation in response
inhibition regions (e.g. the DLPFC).
d) There will be no differences between groups in
prevalence of adverse events and dropout rates.
e) Effects will be maintained at 8-weeks follow-up.
Methods
Overview and study design
This is a two-arm, double-blinded, randomized con-
trolled trial (RCT). Sixty obese patients diagnosed with
BED will be assigned to either: 1) a 20-session treatment
protocol of real rTMS, or 2) a 20-session treatment
protocol of sham rTMS. Participants will be evaluated
for outcome measures before and after the intervention,
with a follow up visit 8 weeks after the end of treatment.
In addition, a control group comprising 30 female indi-
viduals with no lifetime diagnosis of ED (15 obese indi-
viduals without a diagnosis of BED and 15 normal
weight healthy individuals) will be recruited and enrolled
for baseline comparison (biomarkers, neuropsychological
and neuroimaging evaluation). The trial design and
study flow are shown graphically in Figs. 1 and 2, in line
with the SPIRIT 2013 Statement [56].
Participants
The study will be conducted at a specialized outpatient
program for eating disorders (ED) of the Federal University
of São Paulo (UNIFESP), Brazil. Participants will be fe-
males seeking treatment for their ED or referred by
their clinical care providers. Recruitment will also in-
clude individuals attending online advertisement, study
flyers, and newsletters.
All participants will be informed about the study and
asked to sign the informed consent term before any pro-
cedure is conducted. Study intervention will be com-
pleted in approximately 7 weeks.
Enrollment
Inclusion criteria for randomization
Participants are eligible for randomization if they fulfill
the following inclusion criteria:
1. Meet DSM-5 criteria for BED.
2. Age between 18 to 55 years old.
3. Right-handed and able to write, read, and
understand all elements of the study.
4. Females.
5. BMI ≥ 35 kg/m2 and body weight ≤ 150 kg.
6. Laboratory blood tests (fasting glucose, fasting
glucose/insulin ratio, complete blood count, TSH
and T4) within normal range at study enrollment. In
order to exclude participants with diabetes, fasting
glucose levels under 126 mg/dl will be accepted.
Inclusion criteria for controls
Control participants are eligible if:
1. BMI between 19 and 24.99 kg/m2 for normal weight
controls and BMI ≥ 35 kg/m2 (and less than 150 kg)
for obese controls.
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2. Normal menstrual cycle (every 21–35 days) for the
past 6 months.
3. Age between 18 to 55 years old.
4. Right-handed and able to write, read, and
understand all elements of the study.
5. Females.
6. Laboratory blood tests (fasting glucose, fasting
glucose/insulin ratio, complete blood count, TSH
and T4) within normal range at study enrollment.
Exclusion criteria
1. History of head or eye injury or epilepsy.
2. Body metallic implants, pacemaker, claustrophobia
and any other contraindication to fMRI or rTMS.
3. Current use of psychotropic drugs (except for
antidepressants on a stable dose for at least one
month).
4. Current use of any anti-obesity drug (e.g. sibutramine,
orlistat) and medications that are known to reduce
weight, such as Liraglutide and Topiramate (three
months washout period for any medication).
5. Pregnant or breastfeeding.
6. Diabetes Mellitus diagnosis.
7. Major psychiatric disorder requiring immediate
treatment (e.g. Schizophrenia, Bipolar Disorder).
8. Substance dependence (smokers of less than 5
cigarettes/day will be included).
9. Individuals currently receiving any psychological
therapy for ED.
Pre Baseline (T.2): Self-report questionnaires,                        
neuropsychological evaluation, fMRI and biomarkers.




Baseline (T.3): 1st rTMS session + FCT + VAS + FCQ-S 
+ binge eating frequency evaluation + salivary cortisol 
Post-intervention (T.23): Self-report questionnaires, anthropometric measurements, 
neuropsychological evaluation, fMRI and biomarkers.
Enrolment (60 BED randomized participants and 30 non-BED baseline controls)
Preliminary assessment for eligibility (phone or email)
Does the participant consent to the study and meet inclusion 
criteria?
Screening, informed consent (T.0) and 
Pre Baseline assessment (T.1).
No
Yes
8 weeks follow-up (T.24): Self-report 
questionnaires, anthropometric measures and 
binge eating frequency evaluation.





Sessions 2 (T.4) to session 19 (T.21): rTMS intervention
End of treatment (T.22): Final (20th) rTMS session + FCT
+VAS + FCQ-S + BE frequency evaluation + salivary cortisol
(T.22)
Excluded: Do not meet inclusion 
criteria or no longer interested
Excluded
N = 30 (real rTMS)
Fig. 1 A summary of the study design and participants flow during the study
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10.Cushing’s and Turner’s syndrome.
*Control participants will be excluded if they meet
psychiatric disorder criteria based on the MINI Inter-
national Neuropsychiatric Interview 7.0 [57].
Withdrawal criteria
Participants will be withdrawn from the study if they: i)
become pregnant; ii) experience any adverse event which
the study investigator specifies as an indicator that it is
no longer safe for the individual to participate; iii) initi-
ate the use of any medication described as an exclusion
criteria; iv) develop psychotic or manic symptoms, or v)
failure to complete three consecutive rTMS sessions.
Intervention
Following assessment, participants eligible for the study
will undergo a preliminary fMRI, followed by 20 sessions
of neuronavigated rTMS, one session per day, 3 days/
week over approximately 7 weeks. Focal rTMS will be
performed using a Neurosoft device and a ‘figure of
eight’ coil. Brainscience Neuronavigation will be used to
guide the placement of the coil to the target PFC region
using a template MRI for all participants. The coil will
be placed at a 45° angle to the mid-sagittal line to induce
a posterior to anterior current in the underlying neural
tissue. For the real treatment condition, stimulation will
target the left DLPFC at 110 % of the resting motor
threshold. Each session of 10 Hz stimulation will apply
1000 pulses to the left hemisphere, with a duty cycle of
5 s on and 55 s off, for a total stimulation time of
20 min. Sham rTMS treatment will be administered with
the same TMS methodology used for real intervention,
except for the fact that in the sham condition there is no
actual magnetic stimulation. In order to mimic the cuta-
neous sensation and muscle twitching of rTMS without
stimulating the brain, focal electrical stimulation will be
used as a sham rTMS condition. To ensure treatment
adherence, if rTMS sessions are missed, replacement
sessions will be schedule within a week.
Measures
Additional file 1: Table S1 describes the study measures
and timeframe in details.
Diagnosis and eligibility measures
Anthropometric measures Height and weight will be
measured in triplicate using a stadiometer and a scale.
Participants will be backwards and in a hospital gown.
Hip-waist circumference and ratio will be measured in
triplicate also.
Laboratory blood examination Fasting blood samples
will be obtained for a complete blood count, fasting glu-
cose levels, fasting glucose/insulin ratio, TSH, and free
thyroxine (T4). A urine pregnancy test will be collected
if pregnant condition is possible (women in fertile age
and not using a reliable contraceptive method).
Fig. 2 Consort 2010 Flow Diagram
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Diagnostic interviews Psychiatric diagnosis will be
assessed with The Structured Clinical Interview (MINI
7.0). The interview comprises modules representing differ-
ent groups of psychiatric disorders. In order to confirm
BED diagnosis (DSM-5) and collect further information
on ED psychopathology, The Eating Disorder Examination
(EDE 17.0D) will also be applied. The EDE is a semi-
structured diagnostic interview and the gold-standard in-
strument used in the diagnosis of eating disorders [58]. It
has four subscales of symptoms severity (shape, weight
and eating concern and dietary restrain) and a global
score. In addition the number of binge eating episodes
and days during the past month (or 28 days) is carefully
assessed during the interview. Trained professionals will
be conducting these interviews.
TMS/fMRI safety questionnaires These questionnaires
will be administered in order to rule out potential con-
traindications to TMS intervention and/or fMRI exams,
such as, history of epilepsy, metal implanted devices,
brain or eye injury, pregnancy, stroke, etc.).
Clinical measures Medication use and menstrual status
will be assessed based on a questionnaire developed by
the authors.
Primary outcome measures
The primary outcomes of this study are: (1) the change
in the number of BE episodes before and after study
treatment (number of BE episodes at baseline subtracted
from the number of BE episodes at the end of treat-
ment), as measured by participants recording of binge
episodes in the food diary during the previous 15 days to
the baseline visit (first rTMS session, T.3) to the end of
treatment visit (T.23); (2) the change in “urge to eat”
(craving) as measured in a 10 cm VAS (from T3 to T22).
Secondary outcome measures
Self report measures
1. A short and modified version (comprising 8 items)
of the Food Craving Questionnaire-Trait (FCQ-T)
[59]. The FCQ-T was translated and adapted to
Brazilian Portuguese (publication in progress).
This instrument investigates various aspects of food
cravings across different time periods and
situations.
2. Binge Eating Scale (BES) [60]. BE severity will be
examined using the BES, which is composed of 16
items and has been translated and validated to
Portuguese Change in the total mean score from
the baseline visit (T.3) to the end-of treatment
evaluation (T.23) and 8-week follow up (T.24) will
be compared between the two randomized groups.
3. Three Eating Factor Questionnaire (TEF-Q) [61]. The
reduced 21 item version (TEFQ-R21) [62], which has
been translated and adapted to Brazilian Portuguese
[63] will be used. Overall, the questionnaire evaluates
the following aspects: eating cognitive restrain,
emotional eating and control over eating.
4. The Loss of Control over Eating Scale (LOCES) [64]
is an instrument developed to investigate aspects
associated with the loss of control over eating. The
scale has been translated and validated to Brazilian
Portuguese (publication in progress).
5. UPPS Impulsive Behavior Scale [65] was originally
developed with five factors and later reduced to four
factors and 45-items [66]. These factors were divided
as: a) urgency, tendency to experience strong impulses,
b) lack of premeditation, tendency not to think about
the consequences of an act before engaging in it, c)
lack of perseverance, lack of the ability to stay focused
on a task that can be boring or difficult, and d)
sensation seeking, tendency to search for activities that
are exciting, and openness to try new experiences. The
scale is also available in Brazilian Portuguese [67].
6. Depression Anxiety Stress Scales (DASS-21) is a 21-
item self-report scale [68] developed to measure the
negative emotional states of depression, anxiety and
stress during the past week. Each item is rated using
a 4-point severity/frequency scale according to the
corresponding statement. DASS-21 is available in
Brazilian Portuguese [69].
7. Food diary. Participants will be instructed to register
complete food intake in a food diary for seven
consecutive days before the T.3, T.23 and T.24 visits,
and to record BE episodes for 15 consecutive days
before the same time points (T.3, T.23 and T.24).
8. Body Shape Questionnaire (BSQ-34). The
questionnaire has been validated in patients with
eating disorders and includes assessments of body
image. The questions related to body shape
perception and range from 1 to 6. Higher scores on
these scales indicate greater psychopathology. The
questionnaire has been translated and validated to
Brazilian Portuguese [70].
9. The 12-item Short Form Health Survey (SF-12).
This questionnaire measures health-related quality
of life, subdivided in two scales – Physical Health
Component Summary scales (PCS) and Mental
Health Component Summary scales (MCS) [71]. It
has been translated into Brazilian Portuguese [72].
Anthropometric measures will be completed as previ-
ously described.
Biomarkers Blood serum levels of reactive-C protein,
BDNF, adiponectin, TNF-Alpha, IL-6, IL-10, leptin, ghrelin,
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PYY3–36, estradiol and progesterone will be measured in
order to analyze changes in inflammatory response, hor-
mones and neurotrophic factors.
Cognitive evaluation The evaluation will include seven
cognitive tests investigating executive functions such as,
working memory, control inhibition and decision-making,
as described in details in Additional file 2: Table S2.
Neuroimaging Neuroimaging scans will be performed on
a 3 T Magneton Trio Tim System (Siemens, Germany)
scanner. Magnetic Resonance Imaging (MRI) scans will be
acquired for the whole brain structure (T1-weighted,
1 mm resolution). Functional Magnetic Resonance Im-
aging (fMRI) scans for resting state (no task) will be ac-
quired to investigate functional connectivity. T2-weighted
echo-planar images (EPI) depicting blood oxygen level
dependent (BOLD) contrast will be acquired during the
Stroop Word Color Task (SWCT). The SWCT is widely
used as an index of attention and executive control [73].
The task requires the ability to actively inhibit a learned
response in favor of a more voluntary (and difficult) re-
sponse. A SWCT block-design of three conditions (con-
trol/congruent, neutral and incongruent) will be used
during the fMRI. Neuroimaging allows for a deeper under-
standing of brain structures, patterns and activation. The
fMRI exam and the SWCT will be used as tools to investi-
gate brain areas involved in automatic inhibitory re-
sponses during the SWCT. Further, the SWCT allows the
investigation of differences in activation patterns and con-
nectivity in the PFC during the task [74].
Food Challenge Task (FCT): The task was used and
described in previous studies [47]. The FCT requires
participants to watch a film clip (2 min.) followed by ex-
posure of food (10 min.), in order to stimulate craving.
The current study will only use the film clip to stimulate
craving; there will be no food exposure. Participants will
also complete the Visual Analogue Scale (VAS) of “urge
to eat”, “hunger”, “tension” and “mood” and a short and
modified version (comprising 5 items) of the Food Crav-
ing Questionnaire-State (FCQ-S) [59], which was trans-
lated to Brazilian Portuguese and is in the process of
validation. The FCQ-S investigates aspects of food crav-
ing in real time. In addition, salivary cortisol samples will
be collected along with the FCT to examine potential
impact of stress (exposure to food cues).
rTMS tolerability and safety Participants will be pro-
vided with a monitoring record and instructed to record
any experience of adverse events during the rTMS treat-
ment. The monitoring record will be reviewed before
each rTMS session. Tolerability will be based on the
number of adverse events reported (grouped per side ef-
fect type) and number of dropouts due to adverse events
or other reasons. Safety will be measured based on the
occurrence of serious adverse events, such as seizures
(reported as rare in rTMS studies).
Sample size and statistical analysis
To detect the change in craving and BE frequency before
and after treatment intervention, the following parameters
were used to estimate sample size: effect size f = 0.31
(supposed to be small), alpha error probability =0.05,
power = (1-β error probability) = 0.8, number of groups = 2,
number of measurements through the follow-up = 3 and
correlation among repeated measurements = 0.5.
Statistical Inferences: Two different types of analyses
will be used to evaluate the effectiveness of the rTMS. The
first (and standard) method is intention-to-treat (ITT)
that assumes that every patient allocated to be interven-
tion actually received it [75]. The other paradigm, CACE
estimation method [76, 77] will take into account the
compliance status (patient’s adherence to the rTMS).The
compliance status is defined here as at least one of 20 ses-
sion of rTMS; CACE estimation, therefore, provides a
realistic effect under non-adherence phenomenon being
estimated based on the structural equation modeling.
Underlying both paradigms, it will be used growth model-
ing, which examines the development of individuals on
one more outcome variables over the time. In growth
modeling (on contrary of repeated ANOVAS), random ef-
fects are used to capture individual differences in develop-
ment. The corrected significance level (Bonferroni) to be
adopted due to 32 outcomes will be 0,0015. Such proced-
ure will be carried to avoid false discovered rate due to
multiple comparisons. All the statistical inference will be
done via Mplus 7.0. In addition, careful fMRI image acqui-
sition and processing will be completed and analyzed tak-
ing into consideration the limitations of fMRI studies.
Randomization
A simple randomization will be conducted with a 1:1 allo-
cation. A randomization sequence list will be created
using the website www.random.org, which offers true ran-
dom numbers; such randomness comes from atmospheric
noise, which for many purposes is better than the pseudo-
random number algorithms typically used in computer
program. Participants will be randomly assigned following
simple randomization sequence to one of the two treat-
ments. Group 1 for active rTMS and group 2 for sham
rTMS. Patient allocation will be blinded to all participants
and study staff, in exception to the professionals providing
the rTMS treatment and one doctorate student, respon-
sible for allocation concealment. The allocation sequence
will be concealed and sequentially numbered in dark,
sealed and stapled envelopes and locked in a key protected
cabinet file. Allocation implementation will occur pre-
intervention and between the T.2 and T.3 visits.
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Ethical review and trial registration
The protocol has been reviewed and approved by Research
Ethics Committee UNIFESP/EPM in São Paulo, Brazil
(registration number: 26164614.7.0000.5505). It is regis-
tered in www.clinicaltrials.gov (trial ID: NCT02180984).
Discussion
A major criticism of descriptive approaches to psychiatric
nosology concerns the lack of agreement between current
diagnostic categories and findings from neuroscience re-
search. The current descriptive diagnostic system might
not comprise true phenotypes, as most genetic findings
and neural circuit maps appear either to link to several
different currently described psychiatric disorders or to
different subgroups within syndromes. In response, efforts
to incorporate neurobiological-salient dimensions into the
classification of psychiatric disorders have received in-
creasing emphasis in recent years. The Research Domain
Criteria (RDoC) initiative is an example of this new per-
spective. The RDoC was conceived as a dimensional re-
search approach, which views mental disorders as brain
disorders [14], and investigates mental disorders by look-
ing at different aspects, such as behavioral and biological
factors, brain circuits and chemistry.
The current proposal is to use rTMS as a research tool
to advance in the understanding of the different aspects
altered in BED within the RDoC framework. Thus, the
aim of this study is to extend the investigation of the ef-
fects of rTMS on craving and ED psychopathology to the
exam of patterns of comorbidity, neurobiological and
neuropsychological underpinnings, and of potential bio-
markers. Functional approaches, such as the evaluation of
resting state connectivity and task-induced activation,
have great potential to identify targeted neurocognitive
diagnostic markers and may indicate illness severity and
prognosis with increased accuracy. This is the first ran-
domized clinical trial to investigate the rTMS treatment
effects in obese women with BED. Previous studies had
limitations such as small sample sizes, absence of follow
up data and lack of a dimensional approach. In response
to the current shortcomings in knowledge of BED etiology
and the limited treatments available, we hope to support
innovation in the development of more targeted and ef-
fective evidence-based treatments.
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